Skip to main content
Erschienen in: Surgery Today 9/2014

01.09.2014 | Original Article

Treatment of the postoperative recurrence of lung cancer in octogenarians

verfasst von: Manabu Yasuda, Akira Nagashima, Akira Haro, Genkichi Saitoh

Erschienen in: Surgery Today | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Guidelines for the treatment of postoperative recurrent lung cancer in octogenarians do not exist. In this study, we investigated the prognosis of patients with recurrence after the resection of lung cancer and discuss the management of recurrent tumors in octogenarians.

Methods

This study clinicopathologically evaluated 135 octogenarians who underwent resections for lung cancer at a single institution between 1992 and 2010. We retrospectively reviewed the clinical records of 37 patients with confirmed recurrence. The overall survival of the patients and the treatments used for postoperative recurrence were evaluated.

Results

Among 37 patients, six underwent intensive treatment, 14 underwent palliative treatment and 17 received supportive care only. The overall survival rates of the patients in the antitumor treatment groups tended to be associated with a better prognoses than those of the patients in the supportive care only group, but they did not exhibit significantly better prognoses at 1 year (p = 0.202). However, among the patients with a good performance status, the intensive treatment group tended to exhibit prolonged survival. Of the 37 patients with recurrent tumors, five (14 %) died of other diseases.

Conclusions

Antitumor treatment of postoperative recurrent lung cancer in octogenarians may not always improve the survival rate. However, carefully selecting patients for intensive therapy, such as those with a good performance status, may lead to longer survival rates after postoperative recurrence in octogenarians.
Literatur
1.
Zurück zum Zitat Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.PubMedCrossRef Owonikoko TK, Ragin CC, Belani CP, Oton AB, Gooding WE, Taioli E, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol. 2007;25:5570–7.PubMedCrossRef
2.
Zurück zum Zitat Brokx HA, Visser O, Postmus PE, Paul MA. Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. J Thorac Oncol. 2007;2:1013–7.PubMedCrossRef Brokx HA, Visser O, Postmus PE, Paul MA. Surgical treatment for octogenarians with lung cancer: results from a population-based series of 124 patients. J Thorac Oncol. 2007;2:1013–7.PubMedCrossRef
3.
Zurück zum Zitat Osaki T, Shirakusa T, Kodate M, Nakanishi R, Mitsudomi T, Ueda H. Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg. 1994;57:188–92.PubMedCrossRef Osaki T, Shirakusa T, Kodate M, Nakanishi R, Mitsudomi T, Ueda H. Surgical treatment of lung cancer in the octogenarian. Ann Thorac Surg. 1994;57:188–92.PubMedCrossRef
4.
Zurück zum Zitat Hanagiri T, Muranaka H, Hashimoto M, Nagashima A, Yasumoto K. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer. 1999;23:129–33.PubMedCrossRef Hanagiri T, Muranaka H, Hashimoto M, Nagashima A, Yasumoto K. Results of surgical treatment of lung cancer in octogenarians. Lung Cancer. 1999;23:129–33.PubMedCrossRef
5.
Zurück zum Zitat Dominguez-Ventura A, Allen MS, Cassivi SD, Nichols FC 3rd, Deschamps C, Pairolero PC. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection. Ann Thorac Surg. 2006;82:1175–9.PubMedCrossRef Dominguez-Ventura A, Allen MS, Cassivi SD, Nichols FC 3rd, Deschamps C, Pairolero PC. Lung cancer in octogenarians: factors affecting morbidity and mortality after pulmonary resection. Ann Thorac Surg. 2006;82:1175–9.PubMedCrossRef
6.
Zurück zum Zitat Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007;205:729–34.PubMedCrossRef Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007;205:729–34.PubMedCrossRef
7.
Zurück zum Zitat Endoh H, Yamamoto R, Satoh Y, Kuwano H, Nishizawa N. Risk analysis of pulmonary resection for elderly patients with lung cancer. Surg Today. 2013;43:514–20.PubMedCrossRef Endoh H, Yamamoto R, Satoh Y, Kuwano H, Nishizawa N. Risk analysis of pulmonary resection for elderly patients with lung cancer. Surg Today. 2013;43:514–20.PubMedCrossRef
8.
Zurück zum Zitat The Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer. 7th ed. Chiba: The Japan Lung Cancer Society; 2010. The Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer. 7th ed. Chiba: The Japan Lung Cancer Society; 2010.
9.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.PubMedCrossRef
10.
Zurück zum Zitat Blanchard EM, Arnaoutakis K, Hesketh PJ. Lung cancer in octogenarians. J Thorac Oncol. 2010;5:909–16.PubMedCrossRef Blanchard EM, Arnaoutakis K, Hesketh PJ. Lung cancer in octogenarians. J Thorac Oncol. 2010;5:909–16.PubMedCrossRef
11.
Zurück zum Zitat Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:277S–89S.PubMedCrossRef Socinski MA, Crowell R, Hensing TE, Langer CJ, Lilenbaum R, Sandler AB, et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:277S–89S.PubMedCrossRef
12.
Zurück zum Zitat Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRef Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRef
13.
Zurück zum Zitat Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5.PubMedCrossRef Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008;26:60–5.PubMedCrossRef
14.
Zurück zum Zitat Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, et al. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol. 2007;2:141–6.PubMedCrossRef Altundag O, Stewart DJ, Fossella FV, Ayers GD, Wei W, Zhou X, et al. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol. 2007;2:141–6.PubMedCrossRef
15.
Zurück zum Zitat Hesketh PJ, Lilenbaum RC, Chansky K, Dowlati A, Graham P, Chapman RA, et al. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol. 2007;2:494–8.PubMedCrossRef Hesketh PJ, Lilenbaum RC, Chansky K, Dowlati A, Graham P, Chapman RA, et al. Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol. 2007;2:494–8.PubMedCrossRef
16.
Zurück zum Zitat Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer. 2003;40:221–6.PubMedCrossRef Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer. 2003;40:221–6.PubMedCrossRef
17.
Zurück zum Zitat NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–25.PubMedCentralCrossRef NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–25.PubMedCentralCrossRef
18.
Zurück zum Zitat Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.PubMedCrossRef Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543–51.PubMedCrossRef
19.
Zurück zum Zitat Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. J Thorac Oncol. 2010;5:82–9.PubMedCrossRef Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. J Thorac Oncol. 2010;5:82–9.PubMedCrossRef
20.
Zurück zum Zitat Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–6.PubMedCrossRef Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, et al. Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 2007;25:760–6.PubMedCrossRef
21.
Zurück zum Zitat Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:1166–71.PubMedCrossRef Ebi N, Semba H, Tokunaga SJ, Takayama K, Wataya H, Kuraki T, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:1166–71.PubMedCrossRef
22.
Zurück zum Zitat Turner NJ, Muers MF, Haward RA, Mulley GP. Do elderly people with lung cancer benefit from palliative radiotherapy? Lung Cancer. 2005;49:193–202.PubMedCrossRef Turner NJ, Muers MF, Haward RA, Mulley GP. Do elderly people with lung cancer benefit from palliative radiotherapy? Lung Cancer. 2005;49:193–202.PubMedCrossRef
23.
Zurück zum Zitat LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, et al. A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). Br J Cancer. 2011;105:1123–30.PubMedCentralPubMedCrossRef LeCaer H, Barlesi F, Corre R, Jullian H, Bota S, Falchero L, et al. A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study). Br J Cancer. 2011;105:1123–30.PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011;29:3636–42.PubMedCrossRef Caillet P, Canoui-Poitrine F, Vouriot J, Berle M, Reinald N, Krypciak S, et al. Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol. 2011;29:3636–42.PubMedCrossRef
25.
Zurück zum Zitat Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007;43:2161–9.PubMedCrossRef Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive geriatric assessment and its clinical impact in oncology. Eur J Cancer. 2007;43:2161–9.PubMedCrossRef
26.
Zurück zum Zitat Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011;22:1520–7.PubMedCrossRef Biesma B, Wymenga AN, Vincent A, Dalesio O, Smit HJ, Stigt JA, et al. Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. Ann Oncol. 2011;22:1520–7.PubMedCrossRef
27.
Zurück zum Zitat Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.PubMedCrossRef Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.PubMedCrossRef
Metadaten
Titel
Treatment of the postoperative recurrence of lung cancer in octogenarians
verfasst von
Manabu Yasuda
Akira Nagashima
Akira Haro
Genkichi Saitoh
Publikationsdatum
01.09.2014
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 9/2014
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-013-0719-x

Weitere Artikel der Ausgabe 9/2014

Surgery Today 9/2014 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.